Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (US).

[BACKGROUND] A comprehensive quantitative analysis was conducted to examine patient preferences for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment attributes.

[RESEARCH DESIGN AND METHODS] A discrete choice experiment survey was conducted in United States patients with CLL/SLL. Treatment attributes (efficacy, safety, convenience) were identified through literature review and clinical input. Attributes' relative importance and patients' willingness to trade off attributes were calculated using conditional logistic regression.

[RESULTS] Among 200 respondents, attributes with the highest to the lowest importance were impact of atrial fibrillation on quality of life (QoL; 23.9%); progression-free survival (PFS; 18.6%); impacts of headache (17.7%), diarrhea (14.3%), hypertension (13.6%) on QoL; dosing frequency (8.8%); and formulation type (3.1%). Patients preferred treatments with higher efficacy, less impact of AEs on QoL, lower dosing frequency, and tablets over capsules ( < 0.05). Patients were willing to trade off 2.57 and 1.91 years of PFS for less impact of atrial fibrillation and headache on QoL, respectively.

[CONCLUSIONS] Findings suggest that among treatment attributes assessed, the most important attributes for CLL/SLL patients were impact of atrial fibrillation on QoL, PFS, and impact of headache on QoL. Shared decision-making in treatment selection should include informed discussion about efficacy and impact of AEs on QoL.